Physician profile
Jyotsna Kottoor
NPI 1467173989
$1,082.30
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $233 · 2023: $682 · 2024: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $848.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $188.24 | 2023 | Azstarys |
| Ironshore Pharmaceuticals INC. | $171.83 | 2022-2024 | Jornay Pm |
| Lundbeck LLC | $148.98 | 2022-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $123.52 | 2022-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neos Therapeutics, LP | $110.98 | 2022-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.03 | 2023 | |
| Supernus Pharmaceuticals, INC. | $82.41 | 2022-2024 | Qelbree, Qelbree |
| Abbvie INC. | $74.54 | 2023-2024 | |
| Noven Therapeutics, LLC | $44.02 | 2023 | Xelstrym |
| Owp Pharmaceuticals, INC. | $29.64 | 2023 | Lamotrigine, Subvenite |
| Bausch Health US, LLC | $14.11 | 2024 | Wellbutrin, Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jyotsna Kottoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.